SOURCE: Equity news Alert

August 07, 2012 07:30 ET

Immunovative, Inc. Given a "Buy" Rating and $1.70 Price Target

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS ALERT.

NEW YORK, NY--(Marketwire - Aug 7, 2012) - The following is an investment opinion on Immunovative, Inc. (OTCQB: IMUN), Dendreon (NASDAQ: DNDN), Novartis (NYSE: NVS) and NewLink Genetics (NASDAQ: NLNK). Immunovative, Inc. has received a "Speculative Buy" rating and a $1.70 Price Target from Goldman Small Cap Research. The report can be viewed at, www.goldmanresearch.com/IMMUNOVATIVE-INC/View-category.html.

The Goldman Report on Immunovative states that one of the Company's advantages is they have "an easy, cost-effective manufacturing system favorable for patients, providers and payers. By sourcing from one normal blood donor rather than a matched donor, 1 donor can supply 20 patients, which is a huge advantage. Manufacturing is only a 9 day process and in contrast with targeted therapy leader Dendreon (NASDAQ: DNDN), is stable for 24 months, frozen."

In recent immunotherapy news, Novartis (NYSE: NVS) announced a broad based R&D alliance with the University of Pennsylvania to advance novel T-cell immunotherapies to treat cancer and NewLink Genetics (NASDAQ: NLNK) has announced results from their Phase 2 Investigator-initiated study of their Melanoma immunotherapy.

To read more on Immunovative, Inc. please visit www.imuninfo.com

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid Equity News Alert one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information